Trial Profile

A Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab and With Standard Chemotherapy in Patients With Advanced Lung Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 31 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Docetaxel (Primary) ; Etoposide (Primary) ; Paclitaxel (Primary) ; Pemetrexed (Primary) ; Tifcemalimab (Primary) ; Toripalimab (Primary)
Indications Non-small cell lung cancer; Small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Shanghai Junshi Biosciences

27 Mar 2025 Planned End Date changed from 17 Nov 2024 to 17 Nov 2025.
27 Mar 2025 Planned primary completion date changed from 18 Sep 2024 to 18 Sep 2025.
27 Mar 2025 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com